ATXI vs. TRVN, GHSI, KTRA, ELAB, IMNN, CMMB, KPRX, VCNX, ERNA, and MIRA
Should you be buying Avenue Therapeutics stock or one of its competitors? The main competitors of Avenue Therapeutics include Trevena (TRVN), Guardion Health Sciences (GHSI), Kintara Therapeutics (KTRA), Elevai Labs (ELAB), Imunon (IMNN), Chemomab Therapeutics (CMMB), Kiora Pharmaceuticals (KPRX), Vaccinex (VCNX), Eterna Therapeutics (ERNA), and MIRA Pharmaceuticals (MIRA). These companies are all part of the "pharmaceutical preparations" industry.
Trevena (NASDAQ:TRVN) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, community ranking, valuation and profitability.
Avenue Therapeutics has lower revenue, but higher earnings than Trevena. Avenue Therapeutics is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks.
In the previous week, Trevena had 1 more articles in the media than Avenue Therapeutics. MarketBeat recorded 1 mentions for Trevena and 0 mentions for Avenue Therapeutics. Avenue Therapeutics' average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score.
13.6% of Trevena shares are owned by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are owned by institutional investors. 2.4% of Trevena shares are owned by company insiders. Comparatively, 1.8% of Avenue Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Trevena currently has a consensus price target of $5.00, suggesting a potential upside of 1,168.39%. Given Avenue Therapeutics' higher probable upside, research analysts clearly believe Trevena is more favorable than Avenue Therapeutics.
Trevena received 469 more outperform votes than Avenue Therapeutics when rated by MarketBeat users. Likewise, 71.71% of users gave Trevena an outperform vote while only 60.25% of users gave Avenue Therapeutics an outperform vote.
Trevena has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500. Comparatively, Avenue Therapeutics has a beta of -0.1, suggesting that its share price is 110% less volatile than the S&P 500.
Trevena's return on equity of 0.00% beat Avenue Therapeutics' return on equity.
Summary
Trevena beats Avenue Therapeutics on 10 of the 13 factors compared between the two stocks.
Get Avenue Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATXI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avenue Therapeutics Competitors List
Related Companies and Tools
